GFM
SMMT icon

GF Fund Management’s Summit Therapeutics SMMT Stock Holding History

GF Fund Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
16,404
-316
-2% -$5.6K ﹤0.01% 257
2026
Q1 		$317K Buy
16,720
+2,091
+14% +$33.8K 0.01% 247
2025
Q4 		$256K Sell
14,629
-1,353
-8% -$25.5K ﹤0.01% 272
2025
Q3 		$330K Sell
15,982
-2,901
-15% -$70.4K 0.01% 244
2025
Q2 		$402K Sell
18,883
-631
-3% -$14.4K 0.01% 271
2025
Q1 		$376K Buy
19,514
+2,609
+15% +$52.3K 0.01% 275
2024
Q4 		$302K Buy
+16,905
New +$328K 0.01% 256

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

GF Fund Management's SMMT Position: Q2 2026 in Review

GF Fund Management reduced its Summit Therapeutics (SMMT) stake by 1.9% in Q2 2026, selling an estimated $5.6K and leaving 16,404 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #257.

GF Fund Management first reported a position in SMMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $402K in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • GF Fund Management held 16,404 shares of Summit Therapeutics worth $239K as of Q2 2026.
  • GF Fund Management sold 316 Summit Therapeutics shares in Q2 2026, an estimated $5.6K.
  • Summit Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #257 holding.
  • GF Fund Management first reported a position in Summit Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Summit Therapeutics position peaked at $402K in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.